Loading people...
Jean-François Pariseau is a Partner at Amplitude VC, a venture capital firm specializing in building life sciences and biotech companies. He is known for his expertise in company creation and strategic guidance within the industry.
Jean-François Pariseau primarily invests in the life sciences and biotech sectors. His focus areas include novel drug discovery platforms, advanced therapeutic modalities, and innovative medical technologies, with an emphasis on addressing unmet medical needs.
Jean-François Pariseau works as a Partner at Amplitude VC, a leading venture capital firm. Amplitude VC is known for its unique model of actively building and scaling groundbreaking companies in the life sciences industry.
Jean-François Pariseau stands as a distinguished Partner at Amplitude VC, a leading venture capital firm renowned for its unique approach to company building in the life sciences sector. As a key figure at Amplitude, Jean-François is instrumental in identifying, incubating, and scaling innovative biotech and life sciences companies from inception. His investment philosophy centers on translating cutting-edge scientific discoveries into tangible therapeutic solutions that address significant unmet medical needs globally.
With a career spanning over two decades, Jean-François brings a wealth of experience and a deep understanding of the intricate landscape of the life sciences industry. Prior to joining Amplitude VC, he held various senior leadership positions within both established pharmaceutical corporations and agile biotechnology startups. These roles encompassed critical areas such as research and development, business development, and operational management, providing him with a holistic perspective on the entire drug discovery and commercialization pipeline. This extensive operational background equips him with invaluable insights, enabling him to guide portfolio companies through complex scientific and business challenges.
At Amplitude VC, Jean-François is deeply involved in the firm's distinctive model of co-founding and actively building companies. Rather than merely investing, he works closely with scientific founders and management teams to develop robust strategies, secure intellectual property, and assemble world-class talent. His expertise is particularly sought after in areas such as novel drug discovery platforms, advanced therapeutic modalities, and innovative medical technologies. He is passionate about fostering environments where scientific excellence meets strategic business acumen, ensuring that promising research can evolve into successful enterprises.
Jean-François holds a Ph.D. in Biochemistry from McGill University, providing him with a strong scientific foundation that underpins his investment decisions. Further complementing his scientific prowess, he earned an MBA from HEC Montréal, which sharpened his business acumen and strategic thinking. This powerful combination of scientific rigor and business savvy makes him an invaluable asset to Amplitude VC and its portfolio companies. His commitment to driving innovation and his hands-on involvement are pivotal in Amplitude's mission to create globally competitive life sciences companies that make a profound impact on human health.
Jean-François Pariseau is the Co-founder and Partner at Amplitude Ventures, a life sciences venture capital firm based in Montreal, Quebec. Prior to launching the firm in 2018 with Dion Madsen, he spent 17 years as a Partner at the BDC Capital Healthcare Fund and served as an Investment Manager at CDP Capital Technology Ventures. Throughout his 25-year career in biopharma and healthcare investing, Pariseau has backed several notable Canadian biotechnology successes, including Repare Therapeutics and Clementia Pharmaceuticals, which was acquired for $1.3 billion. Under his leadership, Amplitude Ventures closed its inaugural precision medicine fund at $200 million CAD in 2021 and secured a $263 million CAD first close for its second fund in 2024. He holds an MBA from HEC Montréal and currently focuses on building early-stage precision medicine companies at the intersection of biology and artificial intelligence.
